Enzyme replacement therapy for lysosomal storage diseases

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Enzyme replacement therapy (ERT) is approved for six lysosomal storage diseases (LSDs), including Gaucher disease, Fabry disease, mucopolysaccharidosis types I, II, and VI, and Pompe disease.
• Clinical trials confirm the efficacy and safety of ERT for LSDs.
• However, significant challenges impede successful ERT, including immune responses to therapeutic enzymes, enzyme mistargeting, and delivery to intractable tissues.

Purpose of the Study:

• To review the current status and challenges of enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs).
• To highlight the impact of immune reactions and enzyme mistargeting on ERT efficacy.
• To emphasize the need for novel enzyme development targeting specific tissues like the brain and bone.

Main Methods:

• Literature review of clinical trials and research on ERT for LSDs.
• Analysis of factors affecting ERT efficacy, including immunogenicity and tissue penetration.
• Discussion of strategies to overcome ERT limitations.

Main Results:

• Antibody formation negatively impacts therapeutic outcomes in Gaucher disease, Fabry disease, MPS type I, and Pompe disease.
• Enzyme mistargeting due to autophagic buildup is observed in Pompe disease models.
• The brain and bone represent key intractable tissues requiring targeted enzyme delivery.

Conclusions:

• Controlling immune reactions against therapeutic enzymes is crucial for maximizing ERT efficacy.
• Addressing autophagic buildup is essential for improving ERT outcomes, particularly in Pompe disease.
• Developing novel enzymes that effectively target the brain and bone is vital for enhancing the quality of life for LSD patients.